Bottlenecks and opportunities in immunotherapy for glioma:a narrative review  

作　　者：Ying Shi Mengwan Wu Yuyang Liu Ling Chen Xiuwu Bian Chuan Xu 

机构地区：[1]Department of Oncology,Sichuan Academy of Medical Sciences,Sichuan Provincial People's Hospital,University of Electronic Science and Technology of China,Chengdu,Sichuan Province [2]Department of Neurosurgery,Chinese People's Liberation Army(PLA)General Hospital,Beijing [3]Institute of Pathology&Southwest Cancer Center,Southwest Hospital,Third Military Medical University(Army Medical University),Chongqing [4]Integrative Cancer Center&Cancer Clinical Research Center,Sichuan Cancer Hospital&Institute Sichuan Cancer Center,School of Medicine University of Electronic Science and Technology,Chengdu,Sichuan Province,China

出　　处：《Journal of Bio-X Research》2022年第4期151-162,共12页生物组学研究杂志（英文）

基　　金：National Natural Science Foundation of China(No.81873048,to CX);Medico-Engineering Cooperation Funds from University of Electronic Science and Technology of China(No.ZYGX2021YGCX004,to CX);Sichuan Science and Technology Program(No.2021YFH0187,to YS);Medico-Engineering Cooperation Funds from University of Electronic Science and Technology of China(No.ZYGX2021YGCX018,to YS);Fundamental Research Funds for the Central Universities(No.ZYGX2020KYQD002,to YS).

摘　　要：Glioma is the most aggressive brain tumor having invasive ability and a highly heterogeneous phenotype.Many patients with glioma respond poorly to traditional surgery or temozolomide-based chemotherapy.Over the past few decades,developments in immunotherapeutic strategies have provided newer insights into the treatment of gliomas.Immunotherapy is based on the principle of normalization or recovery of T cell-mediated anti-tumor immunoreaction.Different innovative strategies have been used;these include enhancement of immunogenicity by administration of tumor antigens or dendritic cell vaccines,replenishment of cytotoxic T cells by adoptive T cell transfer,repair of exhausted T cells by immune checkpoint inhibitors,and the use of other immune activators such as oncolytic viruses.However,many immunotherapy-based clinical trials did not meet the expected therapeutic endpoints in patients with glioma.Gliomas use unique strategies to generate an immune-suppressive microenvironment;these include limiting immunogenicity and repressing T cell infiltration or activation.This may be addressed by the incorporation of immunotherapy with standard therapy or by use of certain innovative approaches such as tumor-treating fields.In this review,we summarize the updated immunotherapies in glioma and discuss current limitations and future prospects.

关 键 词：chimeric antigen receptor T cells GLIOMA immune checkpoint inhibitor IMMUNOTHERAPY NEOANTIGEN 

分 类 号：R730.51[医药卫生—肿瘤]